Magnetic resonance spectroscopy as a decision tool in multimodality treatment design for localised prostate cancer
Sasso, Giuseppe, Zapotoczna, Aleksandra, Pryor, David, and Simpson, John (2009) Magnetic resonance spectroscopy as a decision tool in multimodality treatment design for localised prostate cancer. Oncology Reviews, 3 . pp. 215-223.
|PDF (Published Version) - Repository staff only - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader|
View at Publisher Website: http://dx.doi.org/10.1007/s12156-009-002...
Predicting the outcome of individual prostate adenocarcinoma can be challenging, especially for patients affected by intermediate or high risk, but localised disease. Natural histories of prostate cancers with similar stage and prognostic factors can differ significantly; and an ongoing debate surrounds the optimal treatment choice for men diagnosed with non-metastatic prostate cancer. A variety of effective therapeutic options are available to be used as a sole modality, or in combination, including surgery, external beam radiotherapy, brachytherapy, and endocrine manipulation. Although these treatments have been used routinely for more than 15 years, there is a paucity of data from randomised trials comparing their results. In addition, most treatment techniques have changed dramatically in the last two decades due to the ongoing healthcare technological revolution. The rapid proliferation of new and expensive therapeutic options (i.e. adaptive radiotherapy, focal ablation, etc.) promises to minimise treatment related side effects and improve local control, however, there is no uniform consensus. Treatment choice is based on the available prognostic factors and life expectancy, along with patient preference, toxicity profiles, the individual institution’s (and clinician’s) experience and resource availability. Unfortunately, our prognostic tools are still limited, as is our ability to precisely predict which subset of patients might benefit from more aggressive therapeutic combinations. Therefore, a significant number of patients receive unnecessary and expensive treatments, whilst others are denied highly technological procedures because of associated resource limitation. This paper aims to analyse the current evidence, cost-effectiveness and controversies, surrounding the nonsurgical treatment of localised prostate cancer, with a focus on radiation and endocrine therapies, and to discuss the role of magnetic resonance spectroscopy, as a decision tool for multimodality treatment design and prediction of response.
|Item Type:||Article (Refereed Research - C1)|
|Keywords:||cost-effectiveness; magnetic resonance spectroscopy; prostate cancer; multimodality treatment|
|FoR Codes:||11 MEDICAL AND HEALTH SCIENCES > 1112 Oncology and Carcinogenesis > 111204 Cancer Therapy (excl Chemotherapy and Radiation Therapy) @ 100%|
|SEO Codes:||92 HEALTH > 9201 Clinical Health (Organs, Diseases and Abnormal Conditions) > 920102 Cancer and Related Disorders @ 100%|
|Deposited On:||02 Jun 2010 11:12|
|Last Modified:||12 Feb 2011 21:37|
Last 12 Months: 0
|Citation Counts with External Providers:|
Repository Staff Only: item control page